| The PRISMA 2020 statement: an updated guideline for reporting systematic reviews | BMJ, The | 2021 | 4.5K |
| Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria | Lancet Neurology, The | 2018 | 2.4K |
| Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial | Lancet, The | 2016 | 2.3K |
| Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 | Critical Care Medicine | 2017 | 1.7K |
| Scoping reviews: time for clarity in definition, methods, and reporting | Journal of Clinical Epidemiology | 2014 | 1.2K |
| Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis | New England Journal of Medicine | 2003 | 1K |
| Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials | PLoS ONE | 2012 | 741 |
| PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews | BMJ, The | 2021 | 666 |
| Family caregiver burden: results of a longitudinal study of breast cancer patients and their principal caregivers | Cmaj | 2004 | 614 |
| Decision aids for patients facing health treatment or screening decisions: systematic review | BMJ: British Medical Journal | 1999 | 577 |
| Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study | JAMA Oncology | 2017 | 572 |
| Derivation and validation of an index to predict early death or unplanned readmission after discharge from hospital to the community | Cmaj | 2010 | 557 |
| The PRISMA 2020 statement: an updated guideline for reporting systematic reviews | Systematic Reviews | 2021 | 513 |
| The PRISMA 2020 statement: An updated guideline for reporting systematic reviews | International Journal of Surgery | 2021 | 461 |
| Differential diagnosis of suspected multiple sclerosis: a consensus approach | Multiple Sclerosis Journal | 2008 | 450 |
| Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial | Lancet Oncology, The | 2013 | 438 |
| Wnt signaling pathway in non-small cell lung cancer | Journal of the National Cancer Institute | 2014 | 405 |
| Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1 | New England Journal of Medicine | 2015 | 382 |
| Incidence of intraoperative hypotension as a function of the chosen definition: literature definitions applied to a retrospective cohort using automated data collection | Anesthesiology | 2007 | 354 |
| Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease | American Journal of Respiratory and Critical Care Medicine | 2001 | 350 |
| Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement | Archives of Neurology | 2005 | 348 |
| The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience | Journal of Nuclear Medicine | 2012 | 344 |
| Cell surface area regulation and membrane tension | Journal of Membrane Biology | 2001 | 340 |
| Expansion of the Human Phenotype Ontology (HPO) knowledge base and resources | Nucleic Acids Research | 2019 | 333 |
| The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index | Journal of Clinical Epidemiology | 2014 | 328 |
